A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma

BACKGROUND: Medulloblastoma (MB) patients with MYC oncogene amplification or overexpression exhibit extremely poor clinical outcomes and respond poorly to current therapies. Epigenetic deregulation is very common in MYC-driven MB. The bromodomain extra-terminal (BET) proteins and histone deacetylase...

Descripción completa

Detalles Bibliográficos
Autores principales: Kling, Matthew J., Kesherwani, Varun, Mishra, Nitish K., Alexander, Gracey, McIntyre, Erin M., Ray, Sutapa, Challagundla, Kishore B., Joshi, Shantaram S., Coulter, Don W., Chaturvedi, Nagendra K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650837/
https://www.ncbi.nlm.nih.gov/pubmed/36357906
http://dx.doi.org/10.1186/s13046-022-02530-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650837/
https://www.ncbi.nlm.nih.gov/pubmed/36357906
http://dx.doi.org/10.1186/s13046-022-02530-y

Ejemplares similares